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PI -Signature Date Introduction
The format for this report is as follows: selected sections of the introduction have been included for reference. Progress to date has been reported in indented paragraphs under the appropriate section of the proposal. Where appropriate, achievement of specific tasks in the statement of work has been addressed.
The incidence rate for breast cancer generally increases with advancing age [1] . It remains unclear which variables may be involved in this relationship, though one candidate is a newly discovered member of the epidermal growth factor family, Cripto-I (CR-1) [2] [3] [4] . Previous results from our laboratory indicate that CR-I expression is increased in old mammary tissue [5] , and that treatment of old mammary cells with tamoxifen in vitro reduces CR-I mRNA levels (our unpublished results). These results suggest that CR-1 may be involved in carcinogenesis in older mammary tissue and also in the hormonal regulation of breast cancer.
CR-I is expressed at low levels in adult murine, spleen, heart, lung, brain, and breast [6, 7] , and at elevated levels during fetal development [6] and during the growth of mammary epithelium during adolescence and pregnancy [7] . CR-1 is expressed in human breast cancer tissues [8, 9] and cell lines (both estrogen receptor positive and negative, [8] ), as well as in colorectal tumors [10] and pancreatic cancer cells [11] . In two separate studies, 75-82% of breast cancer tissue samples were positive for CR-1, whereas 0-13% of adjacent, non-involved tissue samples were positive [8, 9] , implying that CR-I may be involved in growth regulation of breast cancer cells. In addition, overexpression of CR-I in some immortalized murine mammary epithelial cells is sufficient to cause an increase in anchorage-independent growth, but not sufficient for tumor formation in nude mice [12] . Finally, treatment of CR-I-expressing teratoma cells with retinoic acid results in differentiation of the cells and shutoff of CR-1 transcription [2] . All of the currently published data are correlative and provide only circumstantial evidence for a functional role of CR-i in breast cancer.
CR-1 plays a significant role in the neoplastic phenotype of some human colon cancer cell lines [13] . Treatment of CR-i-positive colon cancer cells with antisense RNA (either directly in vitro or by infection with a retroviral antisense expression vector) resulted in decreased CR-1 protein levels, reduction in both anchorage-dependent and -independent growth, and reduced ability to form tumors in nude mice [13] . These results suggest that reduction, or better yet, elimination of .CR-1 expression in CR-i-positive tumor cells may have a significant therapeutic effect.
Hypotheses

1.
Proper expression of Cripto-1 (CR-1) is required for the normal development of the mammary gland epithelial structure. (T.O. 1) 2.
Overexpression of CR-I will increase tumorigenicity of non-tumorigenic or moderately tumorigenic mammary epithelial cell lines. (T.O. 2) 3.
Underexpression of CR-I will decrease tumorigenicity of highly or moderately tumorigenic cell lines. 
Body
Results to date are indented from the previously submitted procedures and methods.
T.O. la. The CAI retroviral vector (gift from P.A.W. Edwards, University of Cambridge) will be used for these experiments. The packaged vector will be produced in GP+E-86 cells, a mousespecific retroviral packaging cell line [14] . Viral supernatants will be harvested, then filtered through 0.45 pgm membranes to remove cells and cellular debris. If necessary, the virus may be concentrated by centrifugation through a 20% sucrose cushion at 34,000 x g for 6 hr, followed by resuspension in 1/100 of the original volume [15] . Viral titers will be determined by infection of +SA cells with serially diluted virus stocks, followed by staining with x-gal (or selection with G418). The number of blue cells (or G418R colonies) will indicate the number of infectious virions per unit volume in the concentrated supernatant.
The epithelial ductal structure in the murine mammary gland does not develop until 3-6 weeks after birth. Therefore it is possible to produce epithelium-free mammary glands by removing the epithelial rudiment at 2-3 weeks of age [16] . It has been demonstrated that mammary epithelial cells transplanted into such a "cleared" gland will form a ductal structure, and that the mammary cells may be modified in vitro prior to implantation [16, 17] . Our results indicate that it is also possible to modify the epithelial rudiment itself by infection with a retrovirus. Thirty mice (60 mammary glands) will be infected with either 2500 cfu (25 p.1 at 10i cfu/ml) of CAI (03-gal only), CA1CR (expressing CR-1), or CAI CRZ (expressing a CR-I-specific ribozyme) in serum-free Dulbecco's modified Eagle's medium (DME) with 80 ptg/ml polybrene; or treated with 25 [.1 DME plus 80 jtg/mi polybrene alone. The infection will be performed by anaesthetizing the mouse, reflecting the skin to expose the #4 (inguinal) mammary gland, and injecting a 25 p.1 virus suspension into the gland. The wound will be closed with surgical clips, and aseptic technique will be maintained throughout as recommended by the WSU IACUC Guidelines for Survival Rodent Surgery. The use of both #4 glands will allow us to directly compare two treatments in the same mouse, any quantitative data may then be compared using a paired T-test; otherwise quantitative comparisons will be made among all groups using ANOVA and Fisher's PLSD. The initial chosen pairings will be CAI with CAiCR and CAICRZ with DME. If other specific pairings are warranted by the findings, the experiment can be repeated.
Three mice from each pairing (thus 3 glands from each treatment) will be sacrificed after I week, and every week thereafter for a total of 5 weeks. This schedule will allow us to follow the development of the mammary epithelium and evaluate the effect of the treatments throughout the process of gland development. In the future, it may be informative to examine the morphology of transduced glands in pregnant or aged mice, due to the higher observed levels of CR-I expression in those glands. Changes in gland morphology may be qualitatively assessed by observation of the whole mounts. If desired, glands can be dissolved out of Permount with xylene and then embedded in paraffin for sectioning. Changes in CR-I expression can be assessed in these sections by immunohistochemistry using a CR-I-specific antibody we have prepared against a synthetic peptide (first described in [10] ).
As reported in the first year annual report, there were technical difficulties with the retroviral system chosen for the gene transduction experiments proposed throughout this grant application. Transduction of mammary epithelium was possible, but expression of the transgene was restricted to the duct end buds. It was not possible to make a completely transgenic epithelial tree. Thus, though SOW Tasks 1-3 were attempted with the retroviral vectors, no conclusive results were obtained.
The issue at hand is how to alter CR-I expression or levels in the developing mammary gland. Since the retroviral strategy does not appear viable, we are left with choosing another vector (e.g. adeno-associated virus) or attempting to add CR-i protein in some sort of slow-release system (e.g. Elvax pellet). There is one report [18] that implantation of a peptide consisting of only the EGF domain of CR-I in Elvax pellets affected the growth and morphology of the developing epithelial tree. However, fulllength native CR-I protein has still not been isolated, and that may give different results than those observed with only a portion of the protein. Therefore, we have chosen to attempt to purify native CR-i and add it back to the developing mammary gland. We have had some success using immunoaffinity columns (Figure 1 ), though purifying enough protein to use in vivo presents a problem. We used Hi Trap-NHS activated columns (Pharmacia Biotech, Uppsala, Sweden) with purified CR67 antibody used throughout this study. Cells (MCF-7 cells in this case, as they make a large amount of CR-i) were lysed in RIPA buffer and the lysate was clarified by centrifugation and passage through a 0.45 [m filter. It was verified by western blot that these treatments did not affect the level of CR-I in the lysate (not shown). Western Blot using CR-67 as the primary antibody. Lane M, markers 57, 43, 29 kD; Lane 1, wash prior to loading the column; Lane 2, flowthrough fraction after loading with cell lysate; Lane 3, wash after loading; Lanes 4-8, serial fractions from the column after loading 100 mM glycine (pH 2.5); Lane 9, cell lysate prior to loading on the column.
As seen in Figure 1 , only one of the three CR-67-reactive species is purified by the column, perhaps due to conformational differences and relative availability of the CR-67 epitope. We are currently attempting to develop better expression systems to isolate more CR-I protein to use in the developing mammary gland. This will be useful not only for this work, but in any future functional studies where intact glycosylated protein is desired.
One key open question regarding CR-I is what proteins it interacts with on target cells. No receptor has been identified to date, though is has been established that CR-I does not bind to the ErbB receptors [19, 20] . We were able to purify enough CR-I to perform a far-western blot on mouse fibroblasts, mouse mammary epithelial cells, and human breast cancer cells. (Figure 2 ). Briefly, lysates from the target cells were subjected to SDS-PAGE and transferred to PVDF. Duplicate blots were exposed to either purified CR-I or BSA, washed, then probed with anti-CR-I antibody (CR-67) in a standard western blot. Bands that are present only on the blots where CR-1 peptide was used prior to the western blot indicate the presence of CR-I binding proteins.
This isolation of CR-I also resulted in some loss of the CR67-antibody from the column, thus the two bands observed in the fraction only lanes. The essential observations are the presence of a new CR-1-binding band at >200 kD in the murine mammary epithelial cells and MDA-MB-231 cells (denoted by arrows). In addition, a band at -80 kD is found in the mouse mammary cells (arrows). Though the MCF-7 cells make a large amount of CR-I protein, there are no differences in the bands present in the far-western and control blots. It is possible that one of these bands represents a CR-I receptor. It has been recently reported that some crosslinking experiments with T.O. lb. For precise quantification of CR-I protein levels, the experiment will be repeated, and glands will be harvested for protein analysis by western blot. CR-I will be detected using the same antibody as for immunohistochemistry.
This will not be performed unless we are able to isolate enough CR-I to use in slowrelease pellets (SOW Task 4).
T.O. 2
We have designed and tested a hammerhead ribozyme [22, 23] that recognizes nucleotides 12-28 of the murine CR-I mRNA and cuts after the GUC triplet at nucleotides 18-20. A search of the GenBank database (FASTA, GCG Wisconsin Package) revealed no significant nucleotide sequence identity to any other published sequence, including related EGF family members.
As described in the first year annual report (and published [24] ), this ribozyme did not act through a catalytic mechanism. It is unclear why the ribozyme is not catalytic. Perhaps it is due to poor folding due to the long regions 5' and 3' of the ribozyme domain in the ribozyme transcript, or it may be due to the site chosen for ribozyme binding. During the course of investigation of the mechanism of ribozyme activity, we were able to obtain a vector for the expression of ribozymes which contains self-cleaving ribozymes which flank the ribozyme of interest 5' and 3' (kindly provided by J. Norris, University of South Carolina Medical School). We have made two additional ribozymes which use this self-splicing system. The first targets the 5' untranslated region at residue 185, and the second targets the coding region at residue 519. We have tested the selfsplicing ability of these two constructs and found it to be intact ( Figure 3 ). The expected transcript before cleavage by the self-splicing ribozymes is 249 nt. Cleavage at both sites should generate fragments of 105, 62, and 82 nt. Cleavage at only one of the sites would generate fragment pairs of 167 and 82 nt or 105 and 144 nt. All of these species can be seen in Figure 3 . The most prominent bands are at 249, 167, 105, and 82. A light band may be seen at 144, and the band at 62 is either not present or too faint to see. This may indicate some problem in one of the cleavages, but the ribozyme should be active whether or not the cleavage is taking place. We found that the 519 ribozyme cleaves well in vitro, while the 185 ribozyme cleaves poorly, if at all (Figure 4 ). Because the complete ribozyme transcripts were added to the reactions, the smaller ribozyme pieces may also be present. There were many nonspecific transcripts present in the samples, but it is apparent that the 519 ribozyme effectively cut both the long and shortened CR-1 transcripts, generating the expected new fragments (indicated by the arrows on the figure). The 185 ribozyme did not apparently cleave the transcript. The CL-S I cell line was derived from a preneoplastic BALB/c mammary nodule, and the -SA, and +SA target cell lines were isolated from a spontaneous adenocarcinoma derived from the same nodule ( [25] ). CL-S I cells are anchorage-dependent and do not form tumors in syngeneic hosts; -SA cells do not form colonies efficiently in soft-agar, but will form tumors in syngeneic hosts after injection in vivo; +SA cells display efficient colony formation in vitro, and are neoplastic and metastatic (pulmonary metastases after intravenous injection) when inoculated into syngeneic hosts in vivo [25] . CR-I expression is strong in +SA cells, slightly lower in -SA cells, and low in CL-SI cells (unpublished results). A CR-I over-expression retroviral vector has also been constructed (CA1CR) and used to infect CL-S1.
T.O. 2a. Changes in the growth phenotype of the transfected clones which show the greatest difference in CR-1 levels from the parental line will be evaluated in vitro by examining growth rate and the relative efficiency of colony formation in soft agar [25] in triplicate cultures of the various transfected lines. Differences in amount of cellular DNA and colony numbers in soft agar will be analyzed using ANOVA and Fisher's PLSD.
As stated in last year's report, overexpression of CR-I in CL-SI cells did not cause any significant change in growth or ability to form colonies in vitro. Transfection of-SA cells with the original ribozyme was effective at reducing CR-I expression, but neither overexpression nor underexpression affected growth on plastic or in soft agar. Transfection of +SA cells did affect growth in soft agar as shown in Figure 5 . Infection with the retroviral vectors appeared to decrease colony formation from the control, though to a lesser degree for the CR-i-containing vector. Transfections with 10 micrograms of plasmid had the most dramatic effects. Transfection with the overexpression Vector dramatically increased colony formation, while transfection ..... ........ ........ ,.-..,,... ,.. . .. ,........, . . Transfection with the expression plasmid alone had no significant effect on colony formation. These experiments essentially conclude Tasks 5-7, though we will repeat them with the new vectors under development (discussed later).
T.O. 2b. The clones analyzed in T.O. 2a will be implanted into syngeneic mice for in vivo analysis. Five x 10' cells will be injected into epithelium-free (cleared) mammary fat pads of 6-8 week old female BALB/c mice. Six to eight week old animals will be used because (1) the fat pads are larger in these animals, so the surgical implantations are mechanically easier to perform; and (2) at three weeks of age, the mice are still in puberty, and we wish to minimize possible effects of the hormonal state of the animal on the results. The mice will be palpated twice per week for tumor development and tumor size will be measured with a caliper. In untreated mice, +SA-derived tumors are typically palpable after 14-21 days [25] . Therefore, mice will be sacrificed at the end of 4 weeks, unless they are moribund prior to that time, in which case they will be sacrificed immediately and the date of sacrifice noted. Mammary tumors will be further evaluated after fixation, clearing and staining of whole mammary glands. Both whole mounts and sections from them will be analyzed with respect to outgrowth pattern of the transplanted cells (normal vs. hyperplastic). Differences in tumor size (and number if separate tumors are generated) will be compared among all cell types by ANOVA and Fisher's PLSD.
The same cell populations (1 x IOl cells) will be injected into the tail vein of 6-8 week old BALB/c mice to evaluate the potential for the formation of pulmonary metastases [25] . Three mice will be used for each of the cell populations, and they will be sacrificed at 4 weeks after inoculation. Differences in pulmonary tumor number and size will be analyzed using ANOVA and Fisher's PLSD.
Last year we reported on the transfer of-SA/pRZECR-1 clones into mice. It is still not clear if the tumors observed were due to reversion of these cells or recruitment of other cells into the tumors (all of which were CR-i-positive). These experiments will be repeated with the new ribozymes as soon as the constructs are finished.
T.O. 3a. Five x 10 5 +SA cells will be implanted into the cleared #4 fat pads of sixteen 6-8 week old mice. The position of the +SA cells in the gland will be marked on the skin surface to facilitate later injection of viral suspensions. The glands will be infected with 2 x 106 cfu (in 2 injections of 25 Wxl at 4 x 10' cfu/p.l) of the 13-gal-expressing CAI retroviral vector in the presence of 80 jig/ml polybrene [27]. Injections will begin from 0-14 days after the implantation of the tumor cells and will be repeated every other day until day 18 all mice will be sacrificed on day 28 after implantation of tumor cells and the glands will be removed for analysis. Glands will be fixed and stained for 13-gal. Tumor size, percentage of infected (13-gal positive) tumor cells, percentage of infected surrounding cells, and distance of viral spread from the injection point will be recorded. The optimal time after implantation of the tumor cells and the maximum time after implantation (and therefore maximum tumor size) allowing efficient infection with the vector will be determined. The planned viral inoculum will result in a vector: target ratio of 4:1 at the time of tumor cell implantation, if all of the transplanted tumor cells survive. Should these vector:target ratios prove insufficient for efficient infection of the tumor, we can either reduce the initial tumor cell dose or attempt to further increase the viral titer. SOW Tasks 9 and 10; these experiments have not yet begun and due to problems with the retroviral constructs will not be attempted as written.
T.O. 4a. The retroviral constructs CAI and CA1CRZ used in T.O. 1 will be used to treat +SA tumors in vivo. +SA tumors will be generated in the cleared #4 mammary fat pads of fifteen 6-8 week old mice as described in T.O. 3. Ten of the mice will be infected with CAI and CA1CRZ at the optimal conditions determined under T.O. 3 (CAI on one side CAI CRZ on the other). The five remaining mice will receive only DME containing 80 jtg/mI polybrene (in both sides) as a control (see Table 4 for a summary). This design will allow a paired comparison (controlling for host variation) between CAI and CAI CRZ, and will allow a general comparison (ANOVA + Fisher's PLSD) among all three groups. Glands will be scored for tumor size, percentage of infected tumor cells, and percentage of infected surrounding cells (determined by 13-gal staining). A group size of ten (glands) for each treatment is used here rather than the six used in T.O. 2, because reliance on infection of the tumor cells rather than using a stably transfected tumor cell line may increase experimental variability.
SOW Task 11; these experiments
have not yet begun but will be attempted with the new vectors as they are developed.
New vectors: We have cloned the murine and human CR-i genes as well as the new 185 and 519 self-splicing ribozymes into the pAdTrackCMV shuttle vector for use with the AdEasy system developed in Vogelstein's laboratory [26] . These shuttle vector constructs have been sequenced and we are proceeding with the construction of the recombinant viruses. We have verified that expression of transgenes from adenoviral vectors continues for at least 35 days after infection of +SA cells, and that at an moi of 50, it is possible to infect essentially 100% of cells. We plan to use these vectors for Tasks 9-11 after verifying their effectiveness at reducing or increasing CR-I expression. One advantage of this approach is that it is unnecessary to clone cells after infection, as essentially all will be expressing the transgene or ribozyme. A disadvantage is that this is a non-replicating vector and will be lost over time due to cell division. This means that this vector is unacceptable for the experiments described in T.O. Key Accomplishments for Years 1 and 2 1. It is possible to eliminate CR-I protein expression through the use of a ribozyme-like molecule, even without catalytic activity. This decrease is substantially better than that previously observed with antisense strategies [13] . This may indicate that RNA molecules with strong secondary structure can be targeted to the extreme 5' end of a message to obtain excellent reduction or elimination of expression. 6. It is possible to purify CR-I using an antibody affinity column, though the amount of protein purified must be increased to be useful as a reagent.
7. Use of the purified CR-I in a far-western blot showed that there are at least two CR-I binding proteins present in human and mouse mammary epithelial cells. identified in adjacent, non-cancerous tissue (3) (4) (5) . CRCripto-1 (CR-i) is a transforming growth factor 1 has also been found in gastric carcinomas (6) and which has been associated with breast, colon, and pan-pancreatic cancer (7). creatic cancer. Overexpression of CR-1 in non-tumoriIncationce (7).
genic mouse mammary epithelial cells and fibroblasts In addition to the descriptive studies cited above, CR results in an increase in anchorage-dependent and 1 expression has been experimentally altered in certain -independent growth in vitro. Reduction of CR-1 ex-cell lines, and the results demonstrate that it acts as a pression in human colon carcinoma or embryonal tera-transforming growth factor. Overexpression of human toma cells results in a decrease in growth in vitro. In CR-1 in immortalized, non-tumorigenic mouse fibroan effort to better define the role of CR-1 in breast blasts, NIH3T3, resulted in a pronounced increase in cancer, we have developed an underexpression vector anchorage-independent growth in vitro (1). Overexfor CR-1 to reduce CR-1 levels in a tumorigenic mouse pression of the human CR-1 gene in the immortalized, mammary epithelial cell line (-SA). This vector spe-non-tumorigenic mouse mammary epithelial line, cifically targets the expression of the murine homolog NOG-8, resulted in increased anchorage-dependent of CR-1 in murine cancer lines and utilizes a hammer-and -independent growth in vitro, but not in tumorigehead ribozyme-like structure directed toward the ex-nicity in vivo (8) . Finally, incubation of two human treme 5' end of the Cripto-1 mRNA. We dramatically mammary carcinoma lines and one nontransformed reduced expression of CR-1 through the expression of mammary epithelial cell line with synthetic peptides this RNA. This is the first use of a ribozyme-like mole-derived from the CR-1 sequence or with conditioned cule to alter Cripto-1 expression. This ribozyme-medium from CHO cells transfected with the human shaped molecule appears to act principally through a CR-1 gene resulted in increased anchorage-dependent block in translation. A possible mechanism for this growth in vitro (9) . block is described, and its implications for modifying In addition to these overexpression studies, reexpression of other bioactive proteins are discussed.
© 1998 Academic Pessponses to reduction of CR-i expression through the use of antisense RNA oligonucleotides or antisense expression vectors have also been assessed. In human colon carcinoma cells (GEO), reduction of CR-1 expresCripto-1 (CR-1) is a member of the Epidermal sion inhibited anchorage-dependent and -independent Growth Factor (EGF) family. It was originally cloned growth in vitro and reduced tumorigenicity in vivo (10) . from human embryonal carcinoma cell line NT2D1 (1), Also, reduction of CR-1 expression in NT2D1 emand the murine homolog was later cloned from mouse bryonal carcinoma cells resulted in decreased anchorembryos (2). CR-1 is expressed in 60-80% of colorectal age-dependent and -independent growth in vitro (11). cancers, but in only 0-7% of normal colon mucosal cells Although these expression reduction studies paint a (3,4) . CR-1 can be detected in several human breast clear picture of the importance of CR-1 expression in cancer cell lines (3, 4) , and has been detected in 75-colon cancer cells and embryonic teratoma cells, the 82% of human breast tumors, with none of the protein data for breast cancer cells are less clear. To gain further insight into the potential role for CR-1 in mam- which was isolated from a spontaneous mouse maam-which expresses the neo gene from an SV40 promoter to allow for mary adenocarcinoma, does not form colonies in soft selection of stable transfectants, and the cloned sequence from the I agar, but does form tumors in viva (12) . cytomegalovirus (CMV) immediate early promoter to provide high levels of expression. The hammerhead construct, pRZECR-1, was Finally, these experiments focus on providing an ef-made by cloning the Cripto-l-specific ribozyme sequence between the fective way to decrease murine CR-1 expression in BamHI and EcoRI sites in pBKCMV. This puts the hammerhead mouse cells. Though the human and murine genes ex-sequence under the control of the strong CMV promoter. Correct hibit 80% homology overall (2), it will be necessary to insertion was established by restriction enzyme analysis and verified by sequencing (Applied Biosystems automated sequencer, Laboracarefully examine the effects of altering CR-1 expres-tory for Biotechnology and Bioanalysis, WSU, Pullman, WA). sion using protein and cells from the same species, Cells and cell culture. The -SA cell line was isolated from a sponrather than simply using the human CR-1 protein in taneous adenocarcinoma that developed within a preneoplastic all cells, as has been done to date. mouse mammary nodule (12) . This line does not form colonies in soft agar, does form tumors in syngeneic hosts after injection in vivo, and is not metastatic. Unless otherwise indicated, all cells were grown MATERIALS AND METHODS in Dulbecco's Modified Eagle's Medium (DMEM, Sigma, St. Louis, MO) supplemented with 10% bovine calf serum (Hyclone, Ogden, Plasmids and constructs. The Cripto-1-specific hammerhead mol-UT). Cells were maintained at 37°C in a 5% CO 2 environment. ecule was synthesized as two complementary single-stranded DNAs, Transfection of pBKCMV (control) and pRZECR-1 into mammary 43 nucleotides long (Eppendorf Custom Oligonucleotides, Madison, tumor cells was accomplished using Lipofectamine (Gibco/BRL, WI). Two Ag of each oligo were mixed and heated to 75'C for 10 Gaithersburg, MD), according to the manufacturer's instructions. minutes. They were allowed to cool slowly to 4°C and then electrophoTwo to ten /g of plasmid was used with 10 M 1 of Lipofectamine for resed on a 3% Metaphor (FMC, Rockland, ME) agarose gel to verify each 35 mm dish of cells. Transfections were performed in the abannealing. The annealed molecule was then ready for cloning into sence of serum (Optimem medium, Gibco/BRL). Transfected cells an expression vector, were refed with DMEM supplemented with 10% bovine calf serum The basic expression construct used in this study was pBKCMV after 24 hr. Stable transfectants were selected, beginning 72 hr after (Stratagene, La Jolla, CA). This is a eukaryotic expression vector the transfection, by growth in the presence of 800 Ag/ml Geneticin (G418, Gibco/BRL). At least 12 G418-resistant clones were isolated -00 ri .-M from each transfection of -SA cells for evaluation of mRNA and proCt4 C1 -tein production. (9) . This peptide is 100% conserved between human and murine CR-1 (2). The polyclonal antiserum was produced by Quality Controlled Biochemicals, Inc., Hopkinton, MA. The peptide was synthesized, purified, conjugated to KLH, and injected into rabbits. Animals were boosted and bled, and the activity of the serum 'VOW was verified by ELISA against the peptide.
Production of the CR-i antiserum (CR-67
46--
Western blotting. Cells were grown to 90% confluence in 10 cmtissue culture dishes, rinsed with PBS (137 mM NaCl, 3 mM KC1, 10 mM Na 2 HPO 4 , 2 mM KH 2 PO 4 ), then lysed in RIPA buffer (150 mM NaCl, 1% NP-40, 0.5% deoxycholate, 0.1% sodium dodecyl sul- FIG. 2 . Western blot of -SA clones transfected with pBKCMV or fate (SDS), 50 mM Tris, pH 7.5) at 4°C. Samples were sonicated on pRZECR-1. Lane kD, molecular weight in kilodaltons; 2-6, -SA clones ice and frozen at -20'C. Identical cell equivalents (roughly 300,000 transfected with pRZECR-1; 7, -SA control clone transfected with cells) of lysates were diluted 1:1 with 2X Laemmli loading buffer (100 pBKCMV. mM Tris, pH 6.8, 4% SDS, 0.2% bromophenol blue, 20% glycerol), supplemented with 13-mercaptoethanol to a final concentration of 5%, heated to 98°C for 10 minutes, and electrophoresed though replicate discontinuous SDS-polyacrylamide gels (5% stacking, pH 6.8, 12% bases of the mRNA showed that this site should be 
Testing of the Ribozyme
RESULTS
The control expression vector (pBKCMV) and the riboConstruction of the CR-1-Specific Ribozyme zyme expression vector (pRZECR-1) were transfected into -SA cells using Lipofectamine. Bulk cultures were Using the published sequence of mouse CR-1 (2), we selected for the presence of the vectors with G418 (Genetdesigned a hammerhead ribozyme (13, 14) which recog-icin), and at least 12 stably-transfected clones were nizes nucleotides 12-28 of the murine CR-1 mRNA and picked from each transfection. For each transfection, proshould cut after the GUC triplet at nucleotides 18-20. tein was harvested from twelve clones and CR-1 expresThis site was chosen for three reasons. First, an RNA sion was tested by western blot using the CR-67 antisefolding analysis (mfold, by Zuker and Jaeger, using rum. Figure 2 shows one -SA/BKCMV control clone and the GCG Wisconsin Software package) of the first 1050 6 -SA/RZECR-1 clones. It was apparent from the western blot that the ribosimilar levels of CR-1 expression (data not shown).
zyme was effective at eliminating CR-1 expression, but not whether this was through an enzymatic or other mal context (25) . In addition, CR-1 appears to act as a mechanism. The cleavage site for the message was too transforming growth factor, and many of these types near the 5' end of the CR-1 message to distinguish of molecules exhibit translational control of expression cleaved from non-cleaved message on a Northern blot. (26) . The ribozyme, a relatively large (800nt) molecule, Therefore we opted for a reverse transcriptase-PCR binds very near the 5' cap, close enough to inhibit bindstrategy. Primers were designed that spanned the ribo-ing of the 40S ribosomal subunit (15) . This circumzyme cut site and would only amplify a message that stance may very efficiently block translation, regardhad not been cleaved by the ribozyme ( Figure 3A) . As less of the ability of the ribozyme to cleave its target. shown in Figure 3B , all clones make uncleaved CR-1 There is evidence for decreased message levels in message. As shown in Figure 3C , most reactions show some of the ribozyme-transfected clones, and it is possisimilar levels (less than 2-fold difference between lanes) ble that this ribozyme acts through mRNA cleavage of actin transcript. -SA/RZECR-1 clones #5, #18, #23, as well. However, there is no correlation between the and #24 show slightly lower levels of actin, but these apparent degree of cleavage activity and level of protein variations are smaller than those seen with CR-1 (up to synthesis suppression. The two clones with the lowest 5.5-fold difference between lanes). After analyzing the CR-1/actin ratios (18 and 24) come from both the group bands densitometrically (Figure 3D ), and normalizing with nearly complete and the group with complete the CR-1 levels to the actin ones, it appears that there elimination of CR-1 protein expression. Therefore, it are reduced levels of CR-1 message in clones -SA/ appears that inhibition of translation is the more impRZECR-1 #18 and 24. Amplification of polyA+ RNA portant mechanism. samples without reverse transcription did not yield any In summary, we have shown that a hammerhead ribofragments (data not shown). Given the data in Figures zyme directed toward the extreme 5' end of the murine 2 and 3, it appears most likely that this hammerhead CR-1 message is effective at reducing CR-1 protein levribozyme is reducing the levels of CR-1 protein primarily els in a tumorigenic murine mammary epithelial cell through a non-cleavage mechanism.
line. This ribozyme appears to act principally through a non-enzymatic mechanism, though it may also cleave DISCUSSION the mRNA in a classic ribozyme fashion. It is highly effective at eliminating CR-1 protein expression, perWhile both antisense RNA and ribozymes can effec-haps due to acting through both inhibition of translation tively reduce expression of target genes (for example and cleavage mechanisms. In general, the targeting of (10, 11, 14, (16) (17) (18) (19) ), we originally chose to develop a ribo-ribozyme-like molecules to the extreme 5' ends of zyme because of its catalytic nature. Antisense oligonu-mRNAs may be a very effective method of reducing procleotides must generally be produced in stoichiometric tein expression in part by reducing the ability of the 40S amounts to eliminate synthesis of the target protein ribosomal subunit to bind the target message. (20) , while a single ribozyme molecule may cleave multiple copies of the target RNA (21, 22) . ACKNOWLEDGMENTS We have now demonstrated that a hammerhead molecule specific for the extreme 5' region of the CR-i
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method of action of this molecule requires some consideration. The first question that must be addressed is REFERENCES the apparent lack of cleavage activity. Many studies have shown that the length of the ribozyme and target
